Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 15 Jul 2026 for Nuvalent, Inc., €558k. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Michael L. Meyers: trading record in brief
This profile gathers the share dealings of Michael L. Meyers across 2 companies, led by Nuvalent, Inc. and Syndax Pharmaceuticals Inc. Over a trading history stretching from 30 December 2021 to 15 July 2026, the count stands at 6 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 15 July 2026, reports a transaction of €558k in Nuvalent, Inc. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Michael L. Meyers
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
5,146 shares@ US$124.000.0065% mcap100.0% of flowClass A Common StockSEC:0001193125-26-305095:0
3,444 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305095:1
2,647 shares0Class A Common StockSEC:0000950170-25-088546:0
2,499 shares0Class A Common StockSEC:0000950170-24-073653:0
1,714 shares@ US$12.3929.5% of flowCommon StockSEC:0001562180-22-001078:0
5,900 shares@ US$8.7770.5% of flowCommon StockSEC:0001562180-22-000035:0
6 of 6 declarations
